ReNeuron opens new base at Swansea University in exosome research partnership

Daniel Bevan - Editor

Subscribe to the Businessin Wales daily newsletter for FREE here.

UK biotechnology firm ReNeuron Group Limited has established a new operational base at Swansea University’s Institute of Life Science (ILS) as part of a strategic collaboration aimed at advancing next-generation exosome therapies.

The move marks a return for the company to South Wales and is expected to strengthen the region’s growing reputation as a centre for life sciences research and development.

Under the partnership, ReNeuron will relocate its operational activity to the university’s ILS, combining the institution’s laboratory facilities and research infrastructure with the company’s expertise in exosome biology.

The project will be led by Steve Conlan and Deya Gonzalez from Swansea University’s Reproductive Biology and Gynaecological Oncology Research Group, and includes funding for a full-time research associate.

Researchers will investigate how the origin of an exosome influences its tropism and its ability to target and act on specific cells.

The study builds on existing proof-of-concept research and aims to demonstrate how ReNeuron’s CustomEX™ platform, which uses stem-cell-derived exosome producer lines to manufacture delivery vehicles that can carry therapeutic cargo at scale, could help medicines reach difficult-to-access organs and cell types.

Deya Gonzalez, Professor of Molecular Medicine at Swansea University, said: “We are thrilled to welcome ReNeuron to the Institute of Life Science.

“This collaboration is a perfect synergy between academic excellence and industrial innovation. By combining our research group’s deep understanding of cellular biology with ReNeuron’s sophisticated CustomEX™ platform, we have a unique opportunity to solve one of medicine’s biggest challenges: the precise delivery of drugs to the cells where they are needed most.

“This partnership not only strengthens our research output but also ensures that Swansea remains at the forefront of the burgeoning exosome therapeutics field.”

Randolph Corteling, Managing Director and Chief Scientific Officer at ReNeuron, said: “We are delighted to be back working in South Wales with Swansea University as we look to increase commercial activity and progress our commitments to research and development.

“Collaboration with Swansea University provides us with the infrastructure and support to leverage our CustomEX™ platform as a new therapeutic pipeline as well as enabling us to grow and progress the business in line with our strategic goals.”